Literature DB >> 21953845

Registration of Observational Studies: perspectives from an industry-based epidemiology group.

Scott Chavers1, Daniel Fife, Mary Wacholtz, Paul Stang, Jesse Berlin.   

Abstract

Registration of randomized clinical trials has become standard practice and is enforced through publication policies and governmental regulations. However, the registration of observational studies remains controversial. In this commentary, we propose that a compromise can be reached on which observation should be registered based on study design and study intent.
Copyright © 2011 John Wiley & Sons, Ltd.

Mesh:

Year:  2011        PMID: 21953845     DOI: 10.1002/pds.2221

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.

Authors:  Marc L Berger; Bradley C Martin; Don Husereau; Karen Worley; J Daniel Allen; Winnie Yang; Nicole C Quon; C Daniel Mullins; Kristijan H Kahler; William Crown
Journal:  Value Health       Date:  2014-03       Impact factor: 5.725

Review 2.  Infrequent and incomplete registration of test accuracy studies: analysis of recent study reports.

Authors:  Daniël A Korevaar; Patrick M M Bossuyt; Lotty Hooft
Journal:  BMJ Open       Date:  2014-01-31       Impact factor: 2.692

3.  Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

Authors:  Xavier Kurz; Susana Perez-Gutthann
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-01-11       Impact factor: 2.890

Review 4.  COVID-19-related research in Africa: a cross-sectional review of the International Clinical Trial Registration Platform (ICTRP).

Authors:  Bassey Edem; Victor Williams; Chukwuemeka Onwuchekwa; Ama Umesi; Marianne Calnan
Journal:  Trials       Date:  2021-10-07       Impact factor: 2.279

5.  Publication bias in recent meta-analyses.

Authors:  Michal Kicinski
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.